A detailed history of Ballentine Partners, LLC transactions in Novartis Ag stock. As of the latest transaction made, Ballentine Partners, LLC holds 18,410 shares of NVS stock, worth $1.79 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
18,410
Previous 17,380 5.93%
Holding current value
$1.79 Million
Previous $1.85 Million 14.43%
% of portfolio
0.04%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$106.13 - $120.89 $109,313 - $124,516
1,030 Added 5.93%
18,410 $2.12 Million
Q2 2024

Aug 06, 2024

BUY
$92.57 - $107.37 $185,140 - $214,740
2,000 Added 13.0%
17,380 $1.85 Million
Q1 2024

Apr 11, 2024

BUY
$95.27 - $108.47 $170,342 - $193,944
1,788 Added 13.15%
15,380 $1.49 Million
Q4 2023

Jan 23, 2024

BUY
$92.27 - $101.54 $215,819 - $237,502
2,339 Added 20.79%
13,592 $1.37 Million
Q3 2023

Oct 19, 2023

BUY
$94.73 - $105.13 $74,173 - $82,316
783 Added 7.48%
11,253 $1.15 Million
Q2 2023

Jul 26, 2023

BUY
$92.52 - $104.91 $222,325 - $252,098
2,403 Added 29.79%
10,470 $1.06 Million
Q1 2023

Apr 27, 2023

BUY
$80.03 - $92.81 $12,804 - $14,849
160 Added 2.02%
8,067 $742,000
Q4 2022

Jan 27, 2023

SELL
$75.55 - $92.52 $134,856 - $165,148
-1,785 Reduced 18.42%
7,907 $0
Q3 2022

Oct 26, 2022

BUY
$74.61 - $87.26 $2,835 - $3,315
38 Added 0.39%
9,692 $736,000
Q2 2022

Aug 09, 2022

SELL
$80.52 - $93.75 $213,458 - $248,531
-2,651 Reduced 21.54%
9,654 $816,000
Q1 2022

May 05, 2022

BUY
$80.11 - $90.62 $293,282 - $331,759
3,661 Added 42.35%
12,305 $1.08 Million
Q4 2021

Feb 14, 2022

BUY
$79.7 - $88.13 $1,594 - $1,762
20 Added 0.23%
8,644 $756,000
Q3 2021

Oct 27, 2021

BUY
$81.78 - $95.14 $42,362 - $49,282
518 Added 6.39%
8,624 $705,000
Q2 2021

Aug 12, 2021

SELL
$85.24 - $94.15 $852 - $941
-10 Reduced 0.12%
8,106 $740,000
Q1 2021

May 11, 2021

SELL
$83.5 - $98.47 $40,915 - $48,250
-490 Reduced 5.69%
8,116 $693,000
Q4 2020

Jan 25, 2021

BUY
$78.07 - $94.43 $15,145 - $18,319
194 Added 2.31%
8,606 $813,000
Q3 2020

Oct 22, 2020

BUY
$82.14 - $91.0 $31,870 - $35,308
388 Added 4.84%
8,412 $732,000
Q2 2020

Jul 31, 2020

SELL
$80.93 - $91.1 $23,712 - $26,692
-293 Reduced 3.52%
8,024 $700,000
Q1 2020

Apr 23, 2020

SELL
$70.67 - $99.01 $36,819 - $51,584
-521 Reduced 5.89%
8,317 $685,000
Q4 2019

Jan 22, 2020

BUY
$84.35 - $95.37 $37,704 - $42,630
447 Added 5.33%
8,838 $837,000
Q3 2019

Oct 21, 2019

BUY
$85.54 - $94.26 $5,389 - $5,938
63 Added 0.76%
8,391 $730,000
Q2 2019

Jul 25, 2019

BUY
$75.4 - $92.8 $27,068 - $33,315
359 Added 4.5%
8,328 $761,000
Q1 2019

May 09, 2019

BUY
$75.32 - $86.15 $25,608 - $29,291
340 Added 4.46%
7,969 $767,000
Q4 2018

Feb 04, 2019

BUY
$73.66 - $82.02 $50,162 - $55,855
681 Added 9.8%
7,629 $655,000
Q3 2018

Oct 30, 2018

BUY
$66.94 - $77.43 $7,965 - $9,214
119 Added 1.74%
6,948 $598,000
Q2 2018

Jul 19, 2018

BUY
$64.91 - $73.36 $519 - $586
8 Added 0.12%
6,829 $516,000
Q1 2018

Apr 26, 2018

BUY
$70.39 - $84.15 $10,347 - $12,370
147 Added 2.2%
6,821 $552,000
Q4 2017

Feb 02, 2018

BUY
$72.33 - $77.64 $13,670 - $14,673
189 Added 2.91%
6,674 $561,000
Q3 2017

Nov 06, 2017

BUY
$74.14 - $77.27 $480,797 - $501,095
6,485
6,485 $557,000

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $209B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Ballentine Partners, LLC Portfolio

Follow Ballentine Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ballentine Partners, LLC with notifications on news.